paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

On the agenda are overall survival data from the IMpower150 study of Tecentriq plus Avastin (bevacizumab) and chemotherapy (carboplatin and paclitaxel) in people with previously-untreated, non-squamous NSCLC, as well

Latest news

Roche eyes September FDA verdict for triple NSCLC therapy

The submission is based on the IMpower150 study, which combined Tecentriq with Avastin (bevacizumab) and the standard first-line NSCLC chemotherapy regimen paclitaxel/carboplatin and doubled the 12-month progression-free ... of carboplatin and
Another Tecentriq win for Roche as Avastin combo boosts survival

The 1, 200 patient trial compared PD-L1 inhibitor Tecentriq with VEGF inhibitor Avastin as a combination as well as each drug individually on top of carboplatin and paclitaxel chemotherapy.
New data could put Roche’s Tecentriq first in squamous lung cancer

The phase III IMpower131 study showed that adding the PD-L1 inhibitor to standard first-line chemotherapy with carboplatin and Celgene’s Abraxane (nab-paclitaxel) in patients with advanced squamous ... the IMpower150 study which compared Tecentriq plus
MSD's Keytruda wins new bladder cancer indication in Europe

on investigator-choice chemotherapy (paclitaxel, docetaxel, vinflumime).
Celgene joins PD-1 race via partnership with BeiGene

BeiGene is also acquiring Celgene's commercial operations in Asia with the right to sell blood cancer therapies Revlimid (lenalidomide) and Vidaza (azacitidine) and Abraxane (albumin-bound paclitaxel) for pancreatic cancer -

More from news
Approximately 10 fully matching, plus 107 partially matching documents found.

Latest Intelligence

Pharma deals in May 2015

Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BMS appoints oncology development head

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager: £40, 000 - £45, 000 benefits

Client Services Director – Healthcare Advertising - London: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Business Unit Head, Medical Communications, London: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director - Med Comms: Great salary and bebefits

Senior Project Manager - Medical Writing: Great salary and bebefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Chief Medical Writer, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Editorial Director – Medical Education (MedComms): Neg

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....